Monoclonal antibodies such as alemtuzumab and rituximab have emerged as important new therapeutic agents for B-cell chronic lymphocytic leukemia (B-CLL). Alemtuzumab binds to CD52, an antigen expressed with high density on most normal and malignant B and T lymphocytes. 1 Results from a phase II trial of subcutaneous (s.c.) alemtuzumab as first-line therapy for B-CLL showed an overall response (OR) rate of 81%, including seven complete responses (CRs) and 26 partial responses (PRs). 2 Notably, the T-cell depletion seems to last longer following firstline alemtuzumab treatment than in patients with advanced B-CLL who had received alemtuzumab as salvage therapy. 3, 4 Therefore, long-term follow-up is particularly important to assess any complications that may arise from alemtuzumabinduced immunosuppression. One potential complication is Richter's syndrome (RS), a transformation to a more aggressive lymphoma or leukemia. The prognosis for these patients is poor, with a median survival of 5-8 months from RS diagnosis. 5 In this paper, we report the long-term follow-up of patients (n ¼ 38) who received s.c. alemtuzumab for up to 18 weeks as first-line therapy for B-CLL in a phase II study. 2 The aims were to assess the time to progression and time to treatment failure (TTTF), incidence of late infectious complications and the incidence of RS. The results were compared with consecutive historical controls (n ¼ 75) from the same geographical region and who matched the inclusion criteria of the phase II study but received other first-line treatment regimens.
Local ethics committee approval was granted for this study. The charts of all patients were reviewed. Patients and controls were evaluated for TTTF, infectious complications and the incidence of RS. The rate of infectious complications was recorded from the start of first-line therapy until first administration of second-line treatment or death, whereas the rate of RS was recorded during the entire follow-up period. Infections were recorded as happening during treatment if they occurred between the start of therapy and 4 weeks after the last cycle of treatment. Response to therapy was evaluated according to 1996 National Cancer Institute (NCI) Working Group criteria, 6 and toxicity was graded according to NCI Common Toxicity Criteria version 2.0. TTTF was defined as the time from the start of first-line treatment to the start of second-line treatment or death and time to progression as defined by NCI criteria. 6 The two-sided w 2 exact test was used to test differences in proportions. The Wilcoxon's Gehan exact test was used to test differences between curves representing TTTF or time to RS.
The clinical characteristics of the alemtuzumab-treated patients and matched historical controls are given in Table 1 . The groups were comparable, except for sex and clinical stage with a higher proportion of Rai stage I in the historical controls (37%) than in the alemtuzumab-treated patients (21%). The median time from B-CLL diagnosis to the last follow-up was 82 months (range, 27-370 months) in patients treated with first-line s.c. alemtuzumab, and 77 months (range, 8-144 months) for the 75 matched historical controls. From the start of first-line therapy until last follow-up, the median times were 64 (13-102) and 61 (4-132) months in the two groups, and median time from diagnosis to the start of first-line treatment was 14 months (range, 0-268) and 7 months (range, 0-103), respectively. Alemtuzumab (30 mg/day, three times per week) was administered s.c. as described previously 2 for up to 18 weeks. Oral anti-infective prophylaxis was given during and for 8 weeks following treatment, consisting of valacyclovir (500 mg twice daily), fluconazole (50 mg/day) and cotrimoxazole (twice daily, 3 times a week). Long-term prophylaxis was not used in any patient. In the control group, first-line treatment consisted of oral chlorambucil with or without corticosteroids (n ¼ 39), purine analogs (cladribine or fludarabine) alone (n ¼ 27) or in combination with idarubicin or cyclophosphamide (n ¼ 3), or other combination chemotherapy (cyclophosphamide, doxorubicin, prednisone (CAP), cyclophosphamide, vincristine, prednisone (CVP) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)) (n ¼ 6), which in one patient was consolidated with an autologous stem cell transplantation. In the control group, infectious prophylaxis was not routinely administered.
Response rates in alemtuzumab-treated patients and controls are shown in Table 2 . As reported previously, seven of 38 (19%) evaluable alemtuzumab-treated patients obtained a CR and 26 (68%) obtained a PR, yielding an (OR) rate of 87% in evaluable patients (81% of intent-to-treat population). 2 These results have recently been confirmed in a prospective randomized first-line phase III study (Hillmen P et al. JCO 2006; 24; abstr. 6511).
The median TTTF in our study was 28 months for the 38 evaluable patients (range, 4-102 þ months) (Figure 1 ), and was 32 months (range, 7-102 þ months) among the 33 patients who responded to alemtuzumab; seven of these (18%) have not yet required second-line therapy after a median follow-up of 80 þ months (range, 67-102 þ months). The median TTTF in the seven patients who achieved a CR was 77 months (range, 23-102 þ ). The median time to progression according to NCI criteria was 14 months (range, 1-102 þ ) and for the seven patients with a CR median 58 months (range, 14-102 þ ). At the Table 1 Clinical characteristics of B-CLL patients who received first-line alemtuzumab therapy (n ¼ 38), and matched historical controls (n ¼ 75) who received other types of first-line therapy Abbreviation: B-CLL, B-cell chronic lymphocytic leukemia. Among the 75 matched historical controls, the OR rate to firstline treatment was 56% (5% CR, 51% PR) ( Table 2 ). The difference in OR rate between alemtuzumab-treated patients and controls was statistically significant (P ¼ 0.01). Among patients with advanced stage (Rai stage 3 or 4), 87% of 23 alemtuzumab-treated patients responded compared with 63% of 32 controls (P ¼ 0.07). The CR rate in these subgroups was 26 and 0%, respectively (P ¼ 0.004). In the control group, median TTTF was 17 months (range, 1-106 þ ) ( Figure 1 ) (P ¼ 0.07 vs alemtuzumab) and 30 months (range, 2-106 þ ) for the 42 patients who responded to first-line treatment. Data on OR rate and TTTF for the different regimens used in control patients are shown in Table 2 . The OR rate in 39 patients who received chlorambucil was 41% (0% CR) (Po0.001 vs alemtuzumab) and 70% (10% CR) in 30 patients who received purine analogs as first-line treatment (not significant vs alemtuzumab).
Infectious complications during therapy are summarized in Table 3 . No NCI grade 4 infections were observed. Grade 3 infections were observed in four patients (10%) and consisted of cytomegalovirus (CMV) reactivation that caused fever without pneumonitis in three patients and one Pneumocystis jiroveci pneumonia (in a patient with no prophylaxis due to allergy to cotrimoxazole). 2 In the matched controls, grade 3 or 4 infections were observed during first-line treatment in 14 patients (19%) and included fever of unknown origin (n ¼ 5), pneumonia (n ¼ 4, one fatal), septicemia (n ¼ 2), CMV (n ¼ 1), herpes zoster (n ¼ 1), dental infection (n ¼ 1) and skin infection (n ¼ 1). The difference in incidence of infections between alemtuzumab-treated patients and controls was statistically not significant.
During long-term unmaintained follow-up, 7/38 alemtuzumab-treated patients (18%) experienced totally 10 episodes of reversible grade 3 infections (Table 3) . These included septicemia (n ¼ 2, at þ 19 and þ 20 months), pneumonia (n ¼ 3, at þ 4, þ 8 and þ 69 months), gastroenteritis (n ¼ 1, at þ 5 months), skin and soft-tissue infections (n ¼ 2, at þ 57 and þ 70 months), postoperative wound infection (n ¼ 1, at þ 69 months) and symptomatic Epstein-Barr virus (EBV) reactivation (n ¼ 1, at þ 19 months). The patient with EBV reactivation had impaired eyesight as the main symptom. Treatment with rituximab was effective on both virus load and symptoms, but several relapses of EBV reactivation requiring repeated rituximab therapy have continued to occur. No grade 4 or fatal infections were recorded in this group. In the 75 matched historical controls, for which the median TTTF was shorter than in the alemtuzumab-treated patients (17 vs 28 months), the incidence of grade 3 or 4 infections during unmaintained follow-up was 11% (8/75). These infections consisted of pneumonia (n ¼ 7, two of which were fatal and two of which were Pneumocystis jiroveci), and Salmonella enteritis (n ¼ 1). The risk of developing a grade 3 or 4 infection during unmaintained follow-up was 10% (4/39) after chlorambucil treatment, and 13% (4/30) after purine analog therapy vs 0/6 after combination chemotherapy. The difference between alemtuzumab-treated patients and controls was statistically not significant.
Sixteen percent (6/38) of the patients treated with alemtuzumab developed RS. The corresponding incidence for the matched historical controls was 12% (9/75) (not significant). The median time from B-CLL diagnosis to RS was 44 months (range, 20-75) for patients treated with alemtuzumab, and 41 months (range, 14-94) for the matched historical controls. The median time from the start of CLL therapy to diagnosis of RS was 16 months (range, 3-32 months) in the six alemtuzumab-treated patients and 36 months (range, 1-84 months) in the nine matched historical controls (not significant). The transformation occurred during unmaintained follow-up in one patient in the control group, and the remaining eight patients had all received at least one line of salvage therapy. In the alemtuzumab group, three patients were diagnosed with RS during unmaintained follow-up and three after salvage therapy, which consisted of a fludarabine-based regimen in two cases and chlorambucil in one. The RS diagnosis was diffuse large B-cell lymphoma (DLBCL) in 14 of the total 15 patients with transformation. One patient among the historical controls was diagnosed with an aggressive T-cell lymphoma. Aggressive chemotherapy against RS was instituted in 13 patients, consisting of CHOP or CHOPlike therapy (n ¼ 8), methyl-GAG, ifosfamide, methotrexate, etoposide (MIME) (n ¼ 3) or dexamethasone, high-dose cytarabine, cisplatin (DHAP) (n ¼ 2), which, in one patient, was consolidated with high-dose chemotherapy and stem cell support. Five patients responded with a CR, two from the study group and three from the historical control group. All responding patients had been treated with CHOP or CHOP-like therapy. Their median TTTF was 45 months (range, 9-61 months) and the median survival 45 months (range, 13-65 months) from the diagnosis of RS. Of the responding patients, 2/5 remain alive after 45 and 51 months, respectively, and one died from B-CLL without recurrence of RS.
The current work represents the first study of long-term follow-up of patients who have received first-line therapy with alemtuzumab for B-CLL. In the absence of randomized trials, retrospective historic comparisons may provide meaningful Letters to the Editor preliminary information with proper considerations. Despite a high proportion of patients with advanced stage, a significantly higher OR rate was observed in the alemtuzumab group than in the historical control group (P ¼ 0.01). Durable responses were also observed: the median TTTF of all alemtuzumab-treated patients was 28 months, compared to 17 months (P ¼ 0.07) in the matched historical controls who received various chemotherapeutic agents as first-line therapy. The response rate and TTTF in our study appears to be similar to those reported with purine analogs as first-line treatment in randomized trials, but possibly somewhat shorter than that of recent randomized trials on combination regimens including fludarabine and cyclophosphamide as first-line treatment of B-CLL. Baseline characteristics of the patients may however be different; therefore, such cross-study comparisons should be viewed with caution.
There was no difference in the total number of patients with grade 3/4 infections during or after therapy between the alemtuzumab-treated group and the matched controls, but there was a shift in the infectious panorama on therapy toward more virus reactivations, especially CMV, among patients treated with alemtuzumab. This is in line with other studies reviewed recently. 7 The patient with clinical EBV reactivation had asymptomatic reactivation before the start of alemtuzumab (data not shown). As the reactivation became symptomatic with increasing viral load after alemtuzumab therapy, a causal relationship must be suspected, even though the reactivation became symptomatic as late as 19 months after the end of alemtuzumab therapy. No other late-occurring opportunistic infections were observed, despite the long-lasting T lymphopenia present in many of these patients. 4 Patients with B-CLL are known to have an increased rate of secondary malignancies and RS. 5 A large retrospective analysis showed an RS rate of 4.9%. 5 In the current study, the rate of RS observed in the 75 matched historical controls was 12%. The RS rate in patients treated with alemtuzumab was similar (16%). Although comparable to the matched historical control population, some studies on other first-line therapies have reported lower RS rates in long-term follow-up. The reason for this difference is not known. A larger proportion of patients in our alemtuzumab study population had advanced disease compared with the historical controls and in contrast to other studies. 8 Whether B-CLL patients in various geographical regions and of different ethnic background could have different risk of developing RS is, to our knowledge, not clear. Most (94%) RS cases in our series were diagnosed as DLBCL, which is consistent with previous reports.
Taken together, our data indicate that, despite severe and long-lasting T-cell suppression, 4 alemtuzumab therapy appears to be safe as first-line therapy, with comparable rates of infectious complications and incidence of RS as for studymatched historical controls from the same geographical region. Given the limitation of this retrospective comparison, our data suggest that further studies are warranted on first-line use of alemtuzumab in B-CLL, especially in combination with fludarabine and other cytostatic drugs.
